• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by LAVA Therapeutics N.V.

    9/26/25 4:01:22 PM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LVTX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    LAVA Therapeutics NV

    (Name of Issuer)


    Common shares, par value (euro) 0.12 per share

    (Title of Class of Securities)


    N51517105

    (CUSIP Number)


    09/19/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    N51517105


    1Names of Reporting Persons

    Shay Capital LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,596,403.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,596,403.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,596,403.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    N51517105


    1Names of Reporting Persons

    Shay Capital Holdings LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,596,403.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,596,403.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,596,403.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    LAVA Therapeutics NV
    (b)Address of issuer's principal executive offices:

    Yalelaan 62, Utrecht, NETHERLANDS, 3584 CM.
    Item 2. 
    (a)Name of person filing:

    Shay Capital LLC Shay Capital Holdings LLC Each a "Filer".
    (b)Address or principal business office or, if none, residence:

    The principal business address of each Filer is 280 Park Avenue, 5th Floor West, New York, NY 10017.
    (c)Citizenship:

    Shay Capital LLC and Shay Capital Holdings LLC - Delaware
    (d)Title of class of securities:

    Common shares, par value (euro) 0.12 per share
    (e)CUSIP No.:

    N51517105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See Item 9 of the cover page for each Filer.
    (b)Percent of class:

    See Item 11 of the cover page for each Filer.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Item 5 of the cover page for each Filer.

     (ii) Shared power to vote or to direct the vote:

    See Item 6 of the cover page for each Filer.

     (iii) Sole power to dispose or to direct the disposition of:

    See Item 7 of the cover page for each Filer.

     (iv) Shared power to dispose or to direct the disposition of:

    See Item 8 of the cover page for each Filer.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Shay Capital LLC
     
    Signature:Elan Foxman
    Name/Title:Chief Financial Officer
    Date:09/26/2025
     
    Shay Capital Holdings LLC
     
    Signature:Elan Foxman
    Name/Title:Chief Financial Officer
    Date:09/26/2025
    Exhibit Information

    Exhibit 1: Joint Filing Agreement

    Get the next $LVTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LVTX

    DatePrice TargetRatingAnalyst
    12/12/2024$11.00 → $2.00Outperform → Market Perform
    Leerink Partners
    12/11/2024Mkt Outperform → Mkt Perform
    JMP Securities
    10/25/2022$9.00Buy
    H.C. Wainwright
    11/16/2021$24.00 → $20.00Outperform
    SVB Leerink
    8/17/2021$26.00 → $24.00Outperform
    SVB Leerink
    More analyst ratings

    $LVTX
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by LAVA Therapeutics N.V.

    SCHEDULE 13G - LAVA Therapeutics NV (0001840748) (Subject)

    9/26/25 4:01:22 PM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by LAVA Therapeutics N.V.

    SCHEDULE 13D/A - LAVA Therapeutics NV (0001840748) (Subject)

    9/23/25 4:52:44 PM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by LAVA Therapeutics N.V.

    SCHEDULE 13D/A - LAVA Therapeutics NV (0001840748) (Subject)

    9/18/25 7:08:03 PM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LVTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Versant Venture Capital Vi, L.P. sold $4,068,829 worth of shares (2,903,403 units at $1.40) (SEC Form 4)

    4 - LAVA Therapeutics NV (0001840748) (Issuer)

    9/23/25 4:33:39 PM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Versant Venture Capital Vi, L.P. sold $2,502,261 worth of shares (1,684,434 units at $1.49) (SEC Form 4)

    4 - LAVA Therapeutics NV (0001840748) (Issuer)

    9/18/25 6:49:18 PM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Cooperatieve Gilde Healthcare Iv U.A. claimed ownership of 5,421,170 shares (SEC Form 3)

    3 - LAVA Therapeutics NV (0001840748) (Issuer)

    4/8/25 6:19:03 PM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LVTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    LAVA Therapeutics downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded LAVA Therapeutics from Outperform to Market Perform and set a new price target of $2.00 from $11.00 previously

    12/12/24 8:11:38 AM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LAVA Therapeutics downgraded by JMP Securities

    JMP Securities downgraded LAVA Therapeutics from Mkt Outperform to Mkt Perform

    12/11/24 7:55:00 AM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on LAVA Therapeutics with a new price target

    H.C. Wainwright initiated coverage of LAVA Therapeutics with a rating of Buy and set a new price target of $9.00

    10/25/22 6:28:17 AM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LVTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    Announced entry into an agreement to be acquired by XOMA Royalty Corporation for between $1.16 and $1.24 per share in cash, plus a contingent value right related to LAVA's two partnered assets and unpartnered programsConsummation of acquisition expected to occur in the fourth quarter of 2025, subject to customary closing conditions and an extraordinary general meeting of shareholdersAnnounced decision to discontinue development of LAVA-1266 for acute myeloid leukemia and myelodysplastic syndrome; wind-down of the program has been initiated UTRECHT, The Netherlands, and PHILADELPHIA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA, " or the "Company")), a clin

    8/13/25 4:55:00 PM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right

    EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and LAVA Therapeutics N.V. ("LAVA") (NASDAQ:LVTX) announced today they have entered a definitive share purchase agreement (the "Purchase Agreement" and the transactions set forth in the Purchase Agreement, the "Transactions") whereby XOMA Royalty will acquire LAVA for (i) between $1.16 and $1.24 per share in cash, consisting of (A) USD $1.16 (the "Base Price Per Share") in cash per share (the "LAVA common stock"), plus (B) an additional amount of cash of up to $0.08 per Share (such amount as finally determined in accordance with the Pur

    8/4/25 7:30:00 AM ET
    $LVTX
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LAVA Reports First Quarter 2025 Financial Results, Provides Business Update

    Focused on evaluation of strategic alternatives, with restructuring and closure of the Netherlands operationsEnrollment in LAVA-1266 Phase 1 continues to progressCash, cash equivalents and short-term investments of $66.6 million as of March 31, 2025 expected to fund operations into 2027 UTRECHT, The Netherlands and PHILADELPHIA, May 14, 2025 (GLOBE NEWSWIRE) --  LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA, " "the Company")), a clinical-stage immuno-oncology company focused on its proprietary Gammabody® bispecific gamma delta T cell engagers, today announced recent corporate highlights and financial results for the first quarter ended March 31, 2025. "LAVA's top priority remains deliverin

    5/14/25 7:30:00 AM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LVTX
    Leadership Updates

    Live Leadership Updates

    View All

    LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors

    UTRECHT, The Netherlands and PHILADELPHIA, March 09, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers, today announced the appointment of Christy J. Oliger to its board of directors effective March 9, 2023. Ms. Oliger brings extensive commercial, portfolio management, and senior leadership experience to the role. Additionally, Stefan Luzi, Ph.D., will step down from his role on the LAVA Board. "As an accomplished leader in the pharmaceutical and biotechnology industry with deep experience in oncology, Ms. Oliger brings over three deca

    3/9/23 8:05:00 AM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer

    UTRECT, The Netherlands and PHILADELPHIA, Feb. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that Dr. Charles Morris has joined LAVA as chief medical officer effective February 6, 2023. Dr. Morris will replace Benjamin Winograd, MD, PhD. "During a 25-year tenure in the industry, Dr. Morris has demonstrated a proven track record of advancing novel oncology product candidates from clinical development through global regulatory approvals," said Stephen Hurly, president and chief executive offi

    2/6/23 7:00:00 AM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results

    LAVA-051 updated interim data from ongoing Phase 1/2a clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia and multiple myeloma to be presented at 2022 American Society of Hematology (ASH) Annual MeetingPresented LAVA-051 clinical pharmacodynamic data demonstrating consistency with mechanism of action data at the Society for Immunotherapy for Cancer (SITC) 2022 Annual MeetingAnnounced exclusive worldwide license agreement with Seagen to advance LAVA-1223, a preclinical bispecific gamma delta T cell engager for EGFR-expressing solid tumorsCash and investments of $92.7 million as of September 30, 2022, plus$50.0 million received from Seagen in October provide cas

    11/16/22 4:05:00 PM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LVTX
    Financials

    Live finance-specific insights

    View All

    XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right

    EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and LAVA Therapeutics N.V. ("LAVA") (NASDAQ:LVTX) announced today they have entered a definitive share purchase agreement (the "Purchase Agreement" and the transactions set forth in the Purchase Agreement, the "Transactions") whereby XOMA Royalty will acquire LAVA for (i) between $1.16 and $1.24 per share in cash, consisting of (A) USD $1.16 (the "Base Price Per Share") in cash per share (the "LAVA common stock"), plus (B) an additional amount of cash of up to $0.08 per Share (such amount as finally determined in accordance with the Pur

    8/4/25 7:30:00 AM ET
    $LVTX
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LAVA Therapeutics to Present Initial Phase 1/2a Clinical Trial Dose Escalation Data of LAVA-051 in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

    UTRECHT, The Netherlands and PHILADELPHIA, June 01, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced the presentation of initial dose-escalation data from the Phase 1/2a clinical trial of LAVA-051 in patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago and virtually June 3-7, 2022. "These dose-escalation data from the first four cohorts of our Phase 1/2a clinical tria

    6/1/22 7:00:00 AM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LVTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by LAVA Therapeutics N.V. (Amendment)

    SC 13D/A - LAVA Therapeutics NV (0001840748) (Subject)

    3/7/24 7:09:56 PM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by LAVA Therapeutics N.V. (Amendment)

    SC 13G/A - LAVA Therapeutics NV (0001840748) (Subject)

    2/14/24 4:26:22 PM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by LAVA Therapeutics N.V. (Amendment)

    SC 13D/A - LAVA Therapeutics NV (0001840748) (Subject)

    11/9/23 4:37:57 PM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care